Determinants of failure of midazolam monotherapy during continuous deep sedation until death: evidence from a French cohort in a palliative care unit
Abstract
Background: Continuous deep sedation until death (CDSUD) is a legally regulated practice in France relying primarily on midazolam as first-line therapy. However, additional sedative agents are frequently required, and determinants of failure of midazolam monotherapy remain poorly understood. This study aimed to identify factors associated with failure of midazolam monotherapy during CDSUD, defined as the need for second- or third-line sedative agents.
Methods: We conducted a retrospective single-centre observational study including all patients undergoing CDSUD in a university hospital palliative care unit between 2020 and 2024. Demographic, clinical, pharmacological, and organisational data were collected. Associations with failure of midazolam monotherapy were assessed using univariable and multivariable logistic regression. Age was modelled using restricted cubic splines to account for non-linear effects.
Results: Among 1,376 patients admitted to the unit, 287 underwent CDSUD with midazolam as first-line treatment. Median age was 69 years (IQR 59–77), and 52.3% were male. Cancer was the main diagnosis (74.2%). Failure of midazolam monotherapy occurred in 211/287 patients (73.5%). Among these patients, escalation consisted of chlorpromazine alone in 134/211 patients (63.5%), propofol alone in 20/211 patients (9.5%), and both agents in 57/211 patients (27%). In multivariable analysis, polypharmacy was independently associated with an increased risk of failure of midazolam monotherapy ( P= .002), both in patients receiving 5–9 medications (OR 3.06, 95% CI 1.60–5.91) and in those receiving ≥ 10 medications (OR 3.05, 95% CI 1.22–8.11). Sedation performed in the context of withdrawal of life-sustaining treatment was also associated with failure of midazolam monotherapy (OR 3.51, 95% CI 1.46–9.88). Age showed a significant non-linear association with outcome ( P <.001). Oxygen therapy within the 24 h preceding sedation induction was associated with a reduced risk of failure (OR 0.35, 95% CI 0.18–0.65).
Conclusions: Failure of midazolam monotherapy during CDSUD is common and associated with polypharmacy, and specific clinical contexts. The non-linear effect of age highlights complex pharmacological responses at end of life. These findings support individualized sedation strategies and early anticipation of combination therapy.
Related
- Conscious Sedation with Dexmedetomidine or Midazolam during Endovascular Thrombectomy in Acute Ischemic Stroke: Protocol of the Multicenter PEACE Randomized Trial
- Palliative Sedation at Home in Patients with Advanced Cancer: A Retrospective Observational Study of Clinical Characteristics and Sedation-Related Outcomes
- Symptom burden profiles and applied medication strategies in the days before and after initiation of palliative sedation in advanced cancer patients: an international prospective multicentre observational study (PALSED)
- Age-Stratified Median Effective Dose of a Continuous Remimazolam Maintenance Infusion for Moderate Sedation During Spinal Anesthesia: A Prospective Up-and-Down Dose-Finding Study.
- Multilevel determinants of palliative care access in 27 European countries
BibTeX
@article{gesson2026determinants,
title = {{Determinants of failure of midazolam monotherapy during continuous deep sedation until death: evidence from a French cohort in a palliative care unit}},
author = {Pauline Gesson and Clémence Houizot and Sandrine Coudol and Jean-François Huon and Olivia Nguyen and Simon Prampart‐Fauvet and Adrien Evin},
journal = {BMC Medicine},
year = {2026},
month = oct,
doi = {10.1186/s12916-026-05282-0},
url = {https://link.springer.com/10.1186/s12916-026-05282-0},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Determinants of failure of midazolam monotherapy during continuous deep sedation until death: evidence from a French cohort in a palliative care unit
AU - Pauline Gesson
AU - Clémence Houizot
AU - Sandrine Coudol
AU - Jean-François Huon
AU - Olivia Nguyen
AU - Simon Prampart‐Fauvet
AU - Adrien Evin
PY - 2026
DA - 2026/10/05
JO - BMC Medicine
DO - 10.1186/s12916-026-05282-0
UR - https://link.springer.com/10.1186/s12916-026-05282-0
AB - Background: Continuous deep sedation until death (CDSUD) is a legally regulated practice in France relying primarily on midazolam as first-line therapy. However, additional sedative agents are frequently required, and determinants of failure of midazolam monotherapy remain poorly understood. This study aimed to identify factors associated with failure of midazolam monotherapy during CDSUD, defined as the need for second- or third-line sedative agents. Methods: We conducted a retrospective single-centre observational study including all patients undergoing CDSUD in a university hospital palliative care unit between 2020 and 2024. Demographic, clinical, pharmacological, and organisational data were collected. Associations with failure of midazolam monotherapy were assessed using univariable and multivariable logistic regression. Age was modelled using restricted cubic splines to account for non-linear effects. Results: Among 1,376 patients admitted to the unit, 287 underwent CDSUD with midazolam as first-line treatment. Median age was 69 years (IQR 59–77), and 52.3% were male. Cancer was the main diagnosis (74.2%). Failure of midazolam monotherapy occurred in 211/287 patients (73.5%). Among these patients, escalation consisted of chlorpromazine alone in 134/211 patients (63.5%), propofol alone in 20/211 patients (9.5%), and both agents in 57/211 patients (27%). In multivariable analysis, polypharmacy was independently associated with an increased risk of failure of midazolam monotherapy ( P= .002), both in patients receiving 5–9 medications (OR 3.06, 95% CI 1.60–5.91) and in those receiving ≥ 10 medications (OR 3.05, 95% CI 1.22–8.11). Sedation performed in the context of withdrawal of life-sustaining treatment was also associated with failure of midazolam monotherapy (OR 3.51, 95% CI 1.46–9.88). Age showed a significant non-linear association with outcome ( P <.001). Oxygen therapy within the 24 h preceding sedation induction was associated with a reduced risk of failure (OR 0.35, 95% CI 0.18–0.65). Conclusions: Failure of midazolam monotherapy during CDSUD is common and associated with polypharmacy, and specific clinical contexts. The non-linear effect of age highlights complex pharmacological responses at end of life. These findings support individualized sedation strategies and early anticipation of combination therapy.
SN - 1741-7015
ER -